Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects-Reference-Cited by-同舟云学术

Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects

Published:2017-07-14 Issue:4 Volume:35 Page:e12272
ISSN:1755-5914
Container-title:Cardiovascular Therapeutics
language:en
Short-container-title:Cardiovasc Ther

Author:

Krittanawong Chayakrit¹²^ORCID,Kitai Takeshi²

Affiliation:

1. Department of Internal Medicine; Icahn School of Medicine at Mount Sinai; New York NY USA

2. Department of Cardiovascular Medicine, Heart and Vascular Institute; Cleveland Clinic; Cleveland OH USA

Publisher

Wiley

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1755-5922.12272/fullpdf

Reference50 articles.

1. Vasopeptidase inhibition: a double-edged sword?;Campbell;Hypertension,2003

2. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

3. Unger EF Approval letter - US Food and Drug Administration 2015 http://eresources.library.mssm.edu:3416/drugsatfda_docs/appletter/2015/207620Orig1s000ltr.pdf

4. 2016 acc/aha/hfsa focused update on new pharmacological therapy for heart failure: an update of the 2013 accf/aha guideline for the management of heart failurea report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America;Yancy;J Am Coll Cardiol,2016

5. Beta-amyloid catabolism: roles for neprilysin (nep) and other metallopeptidases?;Carson;J Neurochem,2002

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subgroup disproportionality analysis of dementia-related adverse events with sacubitril/valsartan across geographical regions;Scientific Reports;2024-09-03

2. Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update;Alzheimer's Research & Therapy;2024-08-01

3. Geographic variation in dementia-related adverse events associated with sacubitril/valsartan: Analysis of the FDA Adverse Event Reporting System;2023-10-31

4. Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective;Journal of Cellular and Molecular Medicine;2023-10-17

5. Functional mutation, splice, distribution, and divergence analysis of impactful genes associated with heart failure and other cardiovascular diseases;Scientific Reports;2023-10-05